COVID-19 in liver transplant patients. Clinical and therapeutic aspects

Guidance on the special care of liver or kidney ...

The efficacy and reliability of hydroxychloroquine remains to be future questionable, enroll patients into clinical trial with remdesivir or favipiravir if available. COVID-19 is characterized by virus-induced endocytosis, dysregulation of innate and adaptive immune responses, inflammation...
Cited by: 1
Author: Adriano Perzor, Chiara Maria Gotti, Giampa...
Published Year: 2020

Transplants | COVID-19 Treatment Guidelines
https://www.covid19treatmentguidelines.nih.gov/special-populations/transplant...

Introduction
Transplant Recipients with COVID
Treatment of COVID-19 in Transp...

Therapy of COVID-19 in solid organ transplant (SOT) and hematopoietic cell transplant (HCT) recipients may be challenging due to the presence of underlying medical conditions, transplant-related cytopenias, and the need for chronic immunosuppressive therapy to prevent graft rejection and graft versus-host disease. Transplant recipients may also potentially have increased exposure to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)...

See more on covid19treatmentguidelines.nih.gov

**PROVISIONAL BEST PRACTICE ADVICE FOR HEALTHCARE PROVIDERS**...
Transplants | COVID-19 Treatment Guidelines
https://www.covid19treatmentguidelines.nih.gov/special-populations/transplant-

Introduction

Treating COVID-19 in solid organ transplant (SOT), hematopoietic cell transplant (HCT), and cellular immunotherapy recipients can be challenging due to the presence of coexisting medical conditions, transplant-related cytopenias, and the need for chronic immunosuppressive therapy to prevent graft rejection and graft-versus-host disease. Transplant recipients may also potentially have increased exposure to SARS-CoV-2.
COVID-19 in liver transplant patients. Clinical and therapeutic aspects

Carmelo Loizzi Segreddi, Alberto Marecuzzo Quinto, Mario Fernandez Ruiz

Abstract
The coronavirus disease 2019 (COVID-19) pandemic has profoundly impacted liver transplant (LT) activity across the world, with notable decreases in the number of donations and procedures in most Western countries, in particular throughout the first
COVID-19 in liver transplant patients: Clinical and therapeutic aspects

Transplants | COVID-19 Treatment Guidelines
https://www.covid19treatmentguidelines.nih.gov/special-populations/transplant-

Introduction
Transplant Recipients with COVID-19
Treatment of Covid-19 in Transplant Recipients

Treating COVID-19 in solid organ transplant (SOT), hematopoietic cell transplant (HCT), and cellular immunotherapy recipients can be challenging due to the presence of coexisting medical conditions, transplant-related cytopenias, and the need for chronic immunosuppressive therapy to prevent graft rejection and graft-versus-host disease. Transplant recipients may also potentially have increased exposure to SARS-CoV-2 given... See more on covid19treatmentguidelines.nih.gov

Liver transplantation in the era of COVID-19
Liver transplantation in the era of COVID-19. Liver transplantation is considered the ultimate solution for patients with end-stage chronic liver disease or acute liver failure. Patients with liver transplant need special care starting from preoperative preparation, surgical intervention ending with postoperative care.
Cited by: 12
Author: Mohamed El Kassas, Mohamed Alborai, ...
Publish Year: 2020

Fatal outcome in a liver transplant recipient with COVID-19
Liver injury is common in patients with COVID-19, but little is known about its clinical presentation and severity in the context of liver transplant. We describe a case of COVID-19 in a patient who underwent transplant 3 years ago for hepatocellular carcinoma. The patient came to clinic with sympto ...
Cited by: 78
Author: Jiao Feng Huang, Kenneth I. Zhong, Jaco...
Publish Year: 2020

Clinical Characteristics and Outcomes of Liver...